Actuate Therapeutics Inc. (ACTU), a clinical-stage biopharmaceutical company developing therapies for the treatment of difficult-to-treat cancers, has a clinical trial milestone this quarter that could be critical to its future.
The company's lead drug candidate is Elraglusib (formerly 9-ING-41), a Glycogen Synthase Kinase-3 Beta (GSK-3ß) inhibitor. GSK-3ß is an enzyme that plays a role in various cellular functions like cell growth and division. By blocking this enzyme, Elraglusib may help to slow down or stop the growth of cancer cells.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com